Forbion Growth Opportunities Fund III Cooperatief U.A. and Forbion Growth III Management B.V. filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 4,428,328 shares of MapLight Therapeutics, Inc. voting common stock as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: 4,428,328 shares of MapLight Therapeutics voting common stock reported by both Forbion entities combined.
- Percent of class: The 4,428,328 shares represent approximately 8.4% of outstanding voting common stock.
- Shares outstanding basis: The percentage is calculated on 52,848,208 shares outstanding, as reported in the issuer's prospectus filed under Rule 424(b)(3) on September 23, 2026.
- Voting and dispositive power: Both reporting persons report zero sole voting or dispositive power, and 4,428,328 shares of shared voting and shared dispositive power each.
- Triggering event date: The date of event requiring this filing is September 30, 2026.
- Jurisdiction: Both reporting persons are organized under the laws of the Netherlands, with offices at Gooimeer 2-35, 1411 DC Naarden, The Netherlands.
Forbion Growth III Entities Report Combined 4,428,328-Share Position in MapLight Therapeutics
According to the filing, Forbion Growth Opportunities Fund III Cooperatief U.A. ("Forbion Growth III COOP") directly owns 4,428,328 shares of voting common stock of MapLight Therapeutics, Inc. (NASDAQ:MPLT), par value $0.0001 per share. The filing further discloses that Forbion Growth III Management B.V. ("Forbion Growth III"), acting as the director of Forbion Growth III COOP, "may be deemed to have voting and investment power over the shares held directly by Forbion Growth III COOP." Both entities are organized under the laws of the Netherlands.
The amended Schedule 13G (Amendment No. 1) was filed on November 16, 2026, with a triggering event date of September 30, 2026. The 4,428,328 shares represent approximately 8.4% of the outstanding voting common stock, based upon 52,848,208 shares outstanding as of the date of the issuer's prospectus filed pursuant to Rule 424(b)(3) on September 23, 2026, according to the filing. Neither reporting person holds any sole voting or sole dispositive power over the reported shares; all voting and dispositive power is reported as shared.
The filing was signed on November 16, 2026, by G.J. Mulder and M.A. van Osch, identified as Directors of Forbion Growth III Management B.V. and as Directors of its Director with respect to Forbion Growth III COOP. MapLight Therapeutics, Inc. is headquartered at 800 Chesapeake Drive, Redwood City, CA 94063, according to the filing.
What Was Disclosed
Two Netherlands-based Forbion entities filed an amended Schedule 13G disclosing combined beneficial ownership of 4,428,328 shares of MapLight Therapeutics voting common stock, equal to approximately 8.4% of the class, as of September 30, 2026.




Please wait processing your request...